[Successful administration of nifekalant hydrochloride for postoperative junctional ectopic tachycardia in congenital cardiac surgery].
Two episode of junctional ectopic tachycardia (JET) caused hemodynamic deterioration early after tetralogy of Fallot repair in an 8-month-old infant. Sinus rhythm resumed in each of the episodes immediately after intravenous administration of nifekalant hydrochloride (NIF), a newly developed Vaughan-Williams class III antiarrhythmic drug in Japan. Although QT interval was modestly prolonged with NIF, no life-threatening ventricular arrhythmia (i.e., torsades de pointes) occurred. NIF might be an effective alternative in the treatment of postoperative JET in congenital cardiac surgery.
Sasaki
Tomoyasu
T
Department of Cardiovascular Surgery, Osaka Medical College, Takatsuki, Japan.
Nemoto
S
S
Ozawa
H
H
Katsumata
T
T
Ozaki
N
N
Okumura
K
K
Katayama
H
H
Tamai
H
H
Kishida
H
H
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy*; D011744:Pyrimidinones / Q000627:therapeutic use*; D013613:Tachycardia, Ectopic Junctional / Q000188:drug therapy* / Q000209:etiology; D013771:Tetralogy of Fallot / Q000601:surgery*
D000889:Anti-Arrhythmia Agents; D011744:Pyrimidinones; C076259:nifekalant